Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013751 | 0.99 | GABRA1 (0.34) | GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL1858922 | 0.91 | GABRA1 (0.31) | GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL5029119 | 0.90 | SLC6A2 (0.34) | GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL11607442 | 0.90 | GABRA1 (0.30) | GABRA1GABRB2 | |
| SCHEMBL25267340 | 0.89 | GABRA1 (0.31) | GABRA1GABRB2 | |
| SCHEMBL2436484 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL7748984 | 0.80 | SLC6A2 (0.32) | GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL11151288 | 0.75 | GABRA1 (0.30) | GABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL23246320 | 0.74 | GABRA1 (0.33) | GABRA1GABRB2 | |
| SCHEMBL7928465 | 0.73 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2863863-A1 | REDUCTION OF TOOTH STAINING DERIVED FROM CATIONIC ANTIMICROBIALS | The Procter & Gamble Company (US) | 2015-04-29 | — | — | EP | claimed |
| WO-2013192463-A1 | REDUCTION OF TOOTH STAINING DERIVED FROM CATIONIC ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 2013-12-27 | — | — | WO | claimed |
| US-20130344120-A1 | Mouth Rinse Emulsions | THE PROCTER & GAMBLE COMPANY | 2013-12-26 | — | — | US | claimed |
| US-20130344011-A1 | Reduction Of Tooth Staining Derived From Cationic Antimicrobials | THE PROCTER & GAMBLE COMPANY | 2013-12-26 | — | — | US | claimed |
| US-12624313-B2 | Suspending polymer composition, and method of use thereof | ISP INVESTMENTS LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260102322-A1 | ORAL CARE COMPOSITIONS COMPRISING CARBOXYLIC ACIDS | PROCTER & GAMBLE (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260083649-A1 | ORAL CARE COMPOSITIONS COMPRISING MINT OIL AND TIN | PROCTER & GAMBLE (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260076894-A1 | ORAL CARE COMPOSITIONS COMPRISING HOPS AND TIN | PROCTER & GAMBLE (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260055445-A1 | ARCHAEAL POLYMERASE AMPLIFICATION | BECTON DICKINSON CO (US) | 2026-02-26 | — | — | US | disclosed |
| US-12497478-B2 | High molecular weight block copolymers comprising repeating units derived from monomers comprising lactam and acryloyl moieties and hydrophilic monomers, compositions, and applications thereof | ISP INVESTMENTS LLC (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250154607-A1 | ISOTHERMAL AMPLIFICATION OF PATHOGENS | BECTON, DICKINSON AND COMPANY | 2025-05-15 | — | — | US | disclosed |
| EP-3664776-B1 | APTAMERS FOR CONSUMER PRODUCT COMPOSITIONS | PROCTER & GAMBLE (US) | 2025-05-14 | — | — | EP | disclosed |
| US-5603920-A | DENTIFRICE CONTAINING SPECIFIED PRECIPITATED SILICA ABRASIVE, ORALLY ACCEPTABLE CARRIER | THE PROCTOR & GAMBLE COMPANY (US) | 1997-02-18 | — | — | US | disclosed |
| US-5589160-A | CLEANING | THE PROCTER & GAMBLE COMPANY (US) | 1996-12-31 | — | — | US | disclosed |
| US-5578294-A | Oral compositions | THE PROCTER & GAMBLE COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| US-5560905-A | A TOOTHPASTE COMPRISING A SARCOSINATE SURFACTANT, A CHELATING TARTARIC ACID, ENDOGLYCOSIDASE, COCOAMIDOPROPYLBETAINE AND SODIUM FLUORIDE; ANTIPLAQUE,-GINGIVITIS AND -TARTAR AGENTS; REDUCED DESQUAMATION | THE PROCTOR & GAMBLE COMPANY (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0676950-A1 | ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |
| US-5431903-A | Enzyem, surfactant, chelate, fluoride compound | THE PROCTER & GAMBLE COMPANY (US) | 1995-07-11 | — | — | US | disclosed |
| WO-1994015579-A1 | ORAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1994-07-21 | — | — | WO | disclosed |
| US-4314990-A | Toothpaste compositions | THE PROCTER & GAMBLE COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083649-A1 | ORAL CARE COMPOSITIONS COMPRISING MINT OIL AND TIN | TAS2R40, SOD1, TAS2R10 | GABRA1 2899/4885GABRB2 2719/4885 |
| US-12497478-B2 | High molecular weight block copolymers comprising repeating units derived from monomers comprising lactam and acryloyl moieties and hydrophilic monomers, compositions, and applications thereof | MRPL9, PRMT9, MRPL19 | GABRA1 1872/4885GABRB2 2456/4885 |
| US-20260102322-A1 | ORAL CARE COMPOSITIONS COMPRISING CARBOXYLIC ACIDS | OTC, ODC1, SDC1 | GABRA1 2366/4885GABRB2 3473/4885 |
| US-20260076894-A1 | ORAL CARE COMPOSITIONS COMPRISING HOPS AND TIN | SOD1, SOD3, HMBS | GABRA1 3816/4885GABRB2 3288/4885 |
| US-20260055445-A1 | ARCHAEAL POLYMERASE AMPLIFICATION | POLL, POLB, POLI | GABRA1 4103/4885GABRB2 4020/4885 |
| US-12624313-B2 | Suspending polymer composition, and method of use thereof | MUC1, ALG1, CHD1 | GABRA1 3998/4885GABRB2 4659/4885 |
| US-20130344011-A1 | Reduction Of Tooth Staining Derived From Cationic Antimicrobials | SOD1, ZRANB2, SLC30A5 | GABRA1 4748/4885GABRB2 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.